Skip to main content
NASDAQ:BBI

Brickell Biotech Stock Forecast, Price & News

$0.84
-0.03 (-3.20 %)
(As of 05/13/2021 02:35 PM ET)
Add
Compare
Today's Range
$0.84
$0.89
50-Day Range
$0.82
$1.21
52-Week Range
$0.47
$2.61
Volume10,632 shs
Average Volume3.05 million shs
Market Capitalization$56.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.34
30 days | 90 days | 365 days | Advanced Chart
Receive BBI News and Ratings via Email

Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter.


Brickell Biotech logo

About Brickell Biotech

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Headlines

Brickell Biotech (BBI) Set to Announce Earnings on Thursday
Brickell Biotech (BBI) Set to Announce Earnings on Thursday
May 6, 2021 |  americanbankingnews.com
Analyzing Novavax (NASDAQ:NVAX) & Brickell Biotech (NASDAQ:BBI)
Analyzing Novavax (NASDAQ:NVAX) & Brickell Biotech (NASDAQ:BBI)
April 30, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BBI
CUSIPN/A
CIKN/A
Phone720-505-4755
Employees13
Year FoundedN/A

Sales & Book Value

Annual Sales$7.92 million
Book Value$0.97 per share

Profitability

Net Income$-23,880,000.00
Net Margins-990.67%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$56.37 million
Next Earnings Date5/13/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

478th out of 2,042 stocks

Biological Products, Except Diagnostic Industry

58th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 1.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Brickell Biotech (NASDAQ:BBI) Frequently Asked Questions

Is Brickell Biotech a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brickell Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Brickell Biotech stock.
View analyst ratings for Brickell Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Brickell Biotech?

Wall Street analysts have given Brickell Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brickell Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Brickell Biotech's next earnings date?

Brickell Biotech is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Brickell Biotech
.

How were Brickell Biotech's earnings last quarter?

Brickell Biotech, Inc. (NASDAQ:BBI) posted its quarterly earnings results on Monday, March, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.06. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1 million. Brickell Biotech had a negative net margin of 990.67% and a negative trailing twelve-month return on equity of 187.45%.
View Brickell Biotech's earnings history
.

What price target have analysts set for BBI?

2 Wall Street analysts have issued 12-month price targets for Brickell Biotech's stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate Brickell Biotech's stock price to reach $5.50 in the next year. This suggests a possible upside of 547.2% from the stock's current price.
View analysts' price targets for Brickell Biotech
or view top-rated stocks among Wall Street analysts.

Who are Brickell Biotech's key executives?

Brickell Biotech's management team includes the following people:
  • Mr. Reginald L. Hardy M.B.A., R.Ph., Co-Founder & Chairman (Age 63, Pay $74k)
  • Attorney Robert Busard Brown, CEO & Director (Age 59, Pay $711k)
  • Mr. Andrew D. Sklawer, Co-Founder, COO & Sec. (Age 36, Pay $492.5k)
  • Mr. Deepak Chadha, Chief R&D Officer (Age 51, Pay $479.83k)
  • Mr. Albert Nicholas Marchio II, Chief Financial Officer (Age 69)
  • Mr. Jose Breton, Controller & Chief Accounting Officer (Age 32)
  • Mr. David R. Mcavoy J.D., Gen. Counsel & Chief Compliance Officer (Age 58)
  • Mr. Gary S. Walker, Chief Marketing Officer (Age 61)
  • Ms. Nancy Seretta, VP & Head of Clinical Operations

Who are some of Brickell Biotech's key competitors?

What other stocks do shareholders of Brickell Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO).

What is Brickell Biotech's stock symbol?

Brickell Biotech trades on the NASDAQ under the ticker symbol "BBI."

Who are Brickell Biotech's major shareholders?

Brickell Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.80%), Bank of New York Mellon Corp (0.09%), Smith Salley & Associates (0.07%) and Fifth Third Bancorp (0.04%). Company insiders that own Brickell Biotech stock include David R Mcavoy, Dennison T Veru and Robert Busard Brown.
View institutional ownership trends for Brickell Biotech
.

Which major investors are buying Brickell Biotech stock?

BBI stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Bank of New York Mellon Corp, Smith Salley & Associates, and Fifth Third Bancorp. Company insiders that have bought Brickell Biotech stock in the last two years include David R Mcavoy, Dennison T Veru, and Robert Busard Brown.
View insider buying and selling activity for Brickell Biotech
or or view top insider-buying stocks.

How do I buy shares of Brickell Biotech?

Shares of BBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brickell Biotech's stock price today?

One share of BBI stock can currently be purchased for approximately $0.85.

How much money does Brickell Biotech make?

Brickell Biotech has a market capitalization of $56.88 million and generates $7.92 million in revenue each year. The company earns $-23,880,000.00 in net income (profit) each year or ($5.11) on an earnings per share basis.

How many employees does Brickell Biotech have?

Brickell Biotech employs 13 workers across the globe.

What is Brickell Biotech's official website?

The official website for Brickell Biotech is www.brickellbio.com.

Where are Brickell Biotech's headquarters?

Brickell Biotech is headquartered at 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301.

How can I contact Brickell Biotech?

Brickell Biotech's mailing address is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. The company can be reached via phone at 720-505-4755 or via email at [email protected]


This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.